Oncotarget

Research Papers:

BRCA2 mutations should be screened early and routinely as markers of poor prognosis: evidence from 8,988 patients with prostate cancer

Ming Cui, Xian-Shu Gao _, Xiaobin Gu, Wei Guo, Xiaoying Li, Mingwei Ma, Shangbin Qin, Xin Qi, Mu Xie, Chuan Peng and Yun Bai

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:40222-40232. https://doi.org/10.18632/oncotarget.16712

Metrics: PDF 797 views  |   HTML 1196 views  |   ?  


Abstract

Ming Cui1, Xian-Shu Gao1, Xiaobin Gu1, Wei Guo2, Xiaoying Li1, Mingwei Ma1, Shangbin Qin1, Xin Qi1, Mu Xie1, Chuan Peng1 and Yun Bai1

1Department of Radiation Oncology, Peking University First Hospital, Peking University, Beijing, China

2Graduate School of Medicine, Hebei North University, Zhangjiakou, Hebei, China

Correspondence to:

Xian-Shu Gao, email: doctorgaoxs@126.com

Keywords: BRCA2, mutation, prostate cancer, survival, molecular classification

Received: January 23, 2017     Accepted: March 21, 2017     Published: March 30, 2017

ABSTRACT

The aim of this study was to focus on clinicopathological characteristics and prognosis in men with prostate cancer (PCa) harboring a breast cancer 2 (BRCA2) gene mutation and to offer convincing evidence to consider BRCA2 mutation as a marker of poor prognosis in the molecular classification of PCa. We searched relevant articles from PubMed, Embase, Web of Science, and the Cochrane Library databases to evaluate the differences in the overall survival (OS) and cancer-specific survival (CSS) between BRCA2 mutation carriers and non-carriers in patients with PCa. We included 525 BRCA2 mutation-carriers and 8,463 non-carriers in total from 10 studies in our meta-analysis. The results showed that carrying a BRCA2 mutation was correlated with a reduced CSS and OS when compared with that of non-carriers, with pooled Hazard Ratios (HRs) of 2.53 (95% confidence interval (CI): 2.10–3.06, P < 0.001) and 2.21 (95% CI: 1.64–2.99, P < 0.001), respectively. The results also demonstrated that BRCA2 mutation-carriers harbored a higher Gleason Score (GS) (> 7), TNM stage (> T3, N1, M1), and risk level than non-carriers. Our meta-analysis showed that a BRCA2 mutation predicted poor survival outcomes in patients with prostate cancer, especially in those undergoing treatments with radiotherapy. Therefore, the use of BRCA2 mutation as a clinical prognostic factor could help stratify the high-risk patients and provide clinical strategies for more effective targeted treatments for patients with prostate cancer.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 16712